Related Experiment Video
Updated: May 26, 2026
04:41
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Long-term intrathecal ziconotide therapy: a case study and discussion
P S Staats1, F Luthardt, J Shipley
1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.
Neuromodulation : Journal of the International Neuromodulation Society
|December 14, 2011
Summary
Ziconotide, a novel neurotoxin from Conus Magus snail venom, offers significant relief for chronic neuropathic pain. This treatment improved a patient's quality of life by reducing severe pain and allodynia.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Chronic neuropathic pain is often intractable, significantly impacting patient quality of life.
- Existing treatments may have undesirable side effects, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the therapeutic efficacy of ziconotide in a patient with severe, untreatable neuropathic pain.
- To assess the long-term effects and tolerability of intrathecal ziconotide administration.
Main Methods:
- Case study of a 48-year-old male with chronic neuropathic pain and tactile allodynia.
- Intrathecal administration of ziconotide following a positive response in a blinded placebo-controlled trial.
- Long-term open-label trial to monitor pain intensity and quality of life.
Main Results:
- Baseline pain intensity was 80 mm on the Visual Analog Scale (VAS).
- Post-treatment pain intensity reduced to 16 mm on the VAS.
- Significant improvement in the patient's quality of life was reported.
Conclusions:
- Intrathecal ziconotide demonstrates potential as an effective treatment for severe chronic neuropathic pain.
- Ziconotide may offer pain relief with fewer side effects compared to alternative treatments.
- This case highlights ziconotide's promise for patients with refractory neuropathic pain.
